Freeline Therapeutics Holdings plc Long Term Debt

Freeline Therapeutics Holdings plc (FRLN) currently reports a long-term debt of $1.7M as of September 2023. That compares with $9.1M in the prior-year period — down 81.2% year over year. Use the charts on this page to explore Freeline Therapeutics Holdings plc's long-term debt history and peer comparisons.

Freeline Therapeutics Holdings plc's long-term debt decreased from $9.1M to $1.7M — a 81.2% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Freeline Therapeutics Holdings plc reported $1.7M in long-term debt as of September 2023. That compares with $9.1M in the prior-year period — down 81.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $1.7M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Freeline Therapeutics Holdings plc, and consider following FRLN for alerts when major investors trade the stock.

Freeline Therapeutics Holdings plc is classified in the Healthcare sector. On long-term debt, it currently shows $1.7M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FRLN with unrelated industries.